terça-feira, 10 de novembro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· December 22, 2025

Eos Energy Honors Outgoing Chair Russ Stidolph for Years of Leadership and Investment and Appoints Industry Veteran Joseph Nigro as Chair of the Board of Directors

View original at globenewswire.com
Eos Energy Honors Outgoing Chair Russ Stidolph for Years of Leadership and Investment and Appoints Industry Veteran Joseph Nigro as Chair of the Board of Directors EDISON, N.J., Dec…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Eos has one of the most advanced long-duration storage manufacturing platforms in the country

    80% confidence
  • Eos is building one of the most important energy-infrastructure platforms and is positioned to play a critical role in the future energy mix

    80% confidence
  • Without Russ' leadership, there would be no Eos

    80% confidence
  • Eos has successfully deployed over 5 GWh of operations in the field

    80% confidence
  • Prototype battery cells built when AltEnergy first invested in Eos cycle twice daily to this day

    80% confidence
  • As power demand accelerates with AI and electrification, long-duration storage will be essential to strengthen the grid and complement existing generation

    80% confidence
  • Eos' technology is uniquely suited to deliver flexibility and reliability for grid storage

    80% confidence
  • Joe Nigro's deep expertise across energy markets, finance, and large-scale operational execution makes him the right leader to guide the Board at this pivotal stage

    80% confidence

Citado nestas reportagens da Via News

O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Q4 2026 Biotech Catalyst Cycle: Data Readouts, FDA Decisions and Capital-Allocation Shifts
From late October to January, mid-cap biotechs move through a dense run of events: ESMO and AHA/AASLD data presentations, Q3 earnings, and FDA PDUFA dates for ivonescimab (Nov 14) and lorundrostat (Dec 22). Alongside the regulatory news, companies are changing how they allocate capital: one lowered FY2026 R&D and SG&A guidance and pushed milestones into 2027, one authorized a $400M buyback, and one scheduled a delisting vote (EGM Nov 19, application Jan 25). Value is concentrating in a few binary regulatory and Phase 3 outcomes (Maritime-1 and ECLIPSE 2/3 readouts around Q1 2027), so sentiment is mixed.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,995
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,995 factos verificados com a fonte5,558 documentos-fonte arquivados
Consulte estes dados → isubstrate.com